SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Press/Media: Research

Period	Jul 18 2025

Media coverage

Title	SpringWorks Therapeutics Receives Conditional EU Approval for EZMEKLY® to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
Media name/outlet	Nasdaq
Country/Territory	United States
Date	7/18/25
URL	https://www.nasdaq.com/articles/springworks-therapeutics-receives-conditional-eu-approval-ezmeklyr-treat-neurofibromatosis
Persons	Michael Schmidt